Bayer Stops Regorafenib Trial Early on Positive Phase III Data

Bayer AG announced positive results from its phase III trial evaluating regorafenib compound for the treatment of patients with metastatic colorectal cancer whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significantly improving overall survival and patients in the placebo arm will be offered treatment with regorafenib, the company said in an e-mailed statement today.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE